Why the study?
Does PF-00489791 reduce urinary albumin-to-creatinine ratio in subjects with overt diabetic nephropathy and macroalbuminuria?
Does PF-00489791 reduce urinary albumin-to-creatinine ratio in subjects with overt diabetic nephropathy and macroalbuminuria?
The PDE5 inhibitor PF-00489791 significantly reduced albuminuria in patients with overt diabetic nephropathy over 12 weeks.
Answers are grounded in this paper and cite their sources.
Supports adjunctive PDE5 inhibition for albuminuria in diabetic nephropathy; extends mechanism evidence to macroalbuminuria.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Scheele et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: